Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZX-101A in relapsed/refractory hematologic malignancies
CTR20213390Phase 2Completed
- Sponsor
- Zenshine Pharmaceuticals Co., Ltd.
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ZX-101A in hematopoietic malignancies, peripheral T-cell lymphoma (PTCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mature B-cell lymphoma, non-Hodgkin lymphoma (NHL), sponsored by Zenshine Pharmaceuticals Co., Ltd.. Started Dec 2021; status: completed.
02
Drugs
ZX-101A
03
Conditions
hematopoietic malignanciesperipheral T-cell lymphoma (PTCL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mature B-cell lymphomanon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on CTR20213390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213390.